Congenital Malformations

New England Journal of Medicine

Volumn 308, Issue 9, 1983, Pages 491-497

  Kalter, Harold ^a   Warkany, Josef ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; AMINOPTERIN; AMPHETAMINE; ANESTHETIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIMALARIAL AGENT; BUSULFAN; CAFFEINE; CANNABIS; CAPTOPRIL; CHLORAMBUCIL; CHLORMETHINE; CLOMIFENE; COCAINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DEXTROPROPOXYPHENE; DIAMORPHINE; DIAZEPAM; DICYCLOVERINE; DOXYLAMINE; DRUG; FLUOROURACIL; IMIPRAMINE; LITHIUM DERIVATIVE; LYSERGIDE; MECLOZINE; MERCAPTOPURINE; METHADONE; METHOTREXATE; NALIDIXIC ACID; NEUROLEPTIC AGENT; PENICILLAMINE; PHENCYCLIDINE; PHENOBARBITAL; PHENYTOIN; PODOPHYLLIN; PROCARBAZINE; PSYCHOTROPIC AGENT; PYRIDOXINE; SPERMICIDAL AGENT; SULFONAMIDE; TOBACCO; TRANQUILIZER; TUBERCULOSTATIC AGENT; VINBLASTINE; VINCRISTINE;

ADVERSE DRUG REACTION; BIRTH DEFECT; CHEMICAL TERATOGENESIS; CONGENITAL DISORDER; CONGENITAL MALFORMATION; DRUG DEPENDENCE; DRUG THERAPY; ETIOLOGY; FETUS; HUMAN; PREGNANCY; PREVENTION; REVIEW; STILLBIRTH; TERATOGENESIS; TERATOGENICITY; THERAPY;

ABNORMALITIES, DRUG-INDUCED; AIR POLLUTANTS, OCCUPATIONAL; ALCOHOL DRINKING; ANESTHETICS; ANTICOAGULANTS; ANTICONVULSANTS; CAFFEINE; DOXYLAMINE; DRUG COMBINATIONS; ESTROGENS; FEMALE; HUMAN; INFANT, NEWBORN; PYRIDOXINE; SMOKING; SPERMATOCIDAL AGENTS; SUBSTANCE-RELATED DISORDERS;

EID: 0020702232     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198303033080904     Document Type: Review

References (123)

1. Beckman G., Beckman L., Nordenson I., Nordström S. Studies of spontaneous abortion, malformations and birth weight in populations exposed to environmental pollutants: theoretical considerations and empirical data. In: Berg K, ed. Genetic damage in man caused by environmental agents. New York: Academic Press, 1979: 317-26.
2. Beckman L., Nordström S. Occupational and environmental risks in and around a smelter in northern Sweden. IX. Fetal mortality among wives of smelter workers. Heredilas. 1982; 97:1-7.
3. Vessey M.P., Nunn J.F. Occupational hazards of anaesthesia. Br Med J. 1980; 281:696-698
4. Lauwerys R., Siddons M., Misson C.B., et al. Anaesthetic health hazards among Belgian nurses and physicians. Int Arch Occup Environ Health. 1981; 48:195-203.
5. Edmonds L., Hatch M., Holmes L., et al. Report of Panel II: guidelines for reproductive studies in exposed human populations. In: Bloom AD, ed. Guidelines for studies of human populations exposed to mutagenic and reproductive hazards. New York: March of Dimes Birth Defects Foundation, 1981: 37-110.
6. Dishotsky N.I., Loughman W.D., Mogar R.E., Lipscomb W.R. LSD and genetic damage: is LSD chromosome damaging, carcinogenic, mutagenic, or teratogenic? Science. 1971; 172:431-440
7. Long S.Y. Does LSD induce chromosome damage and malformation?: a review of the literature. Teratology. 1972; 6:75-90.
8. Rothstein P., Gould J.B. Born with a habit: infants of drug-addicted mothers. Pediatr Clin North Am. 1974; 21:307-321
9. Fried P.A. Marihuana use by pregnant women and effects on offspring: an update. Neurobehav Toxicol Teratol. 1982; 4:451-454
10. Finnegan L.P. The effects of narcotics and alcohol on pregnancy and the newborn. Ann NY Acad Sci. 1981; 362:136-157
11. Martin J.C. An overview: maternal nicotine and caffeine consumption and offspring outcome. Neurobehav Toxicol Teratol. 1982; 4:421-428
12. Kurppa K., Holmberg P.C., Kuosma E., Saxén L. Coffee consumption during pregnancy. N Engl J Med. 1982; 306:1548.
13. Linn S., Schoenbaum S.C., Monson R.R., Rosner B., Stubblefield P.G., Ryan K.J. No association between coffee consumption and adverse outcomes of pregnancy. N Engl J Med. 1982; 306:141-145
14. Rosenberg L., Mitchell A.A., Shapiro S., Slone D. Selected birth defects in relation to caffeine-containing beverages. JAMA. 1982; 247:1429-1432
15. Borlée I., Lechat M.F., Bouckaert A., Misson C. Le café, facteur de risque pendant la grossesse? Louvain Med. 1978; 97:279-284
16. Hogue C.J. Coffee in pregnancy. Lancet. 1981; 1:554.
17. Landesman-Dwyer S., Emanuel I. Smoking during pregnancy. Teratology. 1979; 19:119-25
18. Abel E.L. Smoking during pregnancy: a review of effects on growth and development of offspring. Hum Biol. 1980; 52:593-625.
19. Johnston C. Cigarette smoking and the outcome of human pregnancies: a status report on the consequences. Clin Toxicol. 1981; 18:189-209.
20. Harlap S., Shiono P.H. Alcohol, smoking, and incidence of spontaneous abortions in the first and second trimester. Lancet. 1980; 2:173-176
21. Clarren S.K., Smith D.W. The fetal alcohol syndrome. N Engl J Med. 1978; 298:1063-1067
22. Hanson J.W., Streissguth A.P., Smith D.W. The effects of moderate alcohol consumption during pregnancy on fetal growth and morphogenesis. J Pediatr. 1978; 92:457-460
23. Jones K.L., Smith D.W. The fetal alcohol syndrome. Teratology. 1975; 12:1-10.
24. Russell M. Intrauterine growth in infants born to women with alcoholrelated psychiatric diagnoses. Alcohol Clin Exp Res. 1977; 1:225-232
25. Majewski F. Alcohol embryopathy: some facts and speculations about pathogenesis. Neurobehav Toxicol Teratol, 1981; 3:129-144
26. Ouellete E.M., Rosett H.L., Rosman N.P., Weiner L. Adverse effects on offspring of maternal alcohol abuse during pregnancy. N Engl J Med. 1977; 297:528-530
27. Kaminski M., Runieau C., Schwartz D. Alcohol consumption in pregnant women and the outcome of pregnancy. Alcohol Clin Exp Res. 1978; 2:155-163
28. Kaminski M., Franc M., Lebouvier M., du Mazaubrun C., Rumeau-Rouquette C. Moderate alcohol use and pregnancy outcome. Neurobehav Toxicol Teratol. 1981; 3:173-181
29. Mau G. Moderate alcohol consumption during pregnancy and child development. Eur J Pediatr. 1980; 133:233-237
30. Tennes K., Blackard C. Maternal alcohol consumption, birth weight, and minor physical anomalies. Am J Obstet Gynecol. 1980; 138:774-780
31. Kline J., Shrout P., Stein Z., Susser M., Warburton D. Drinking during pregnancy and spontaneous abortion. Lancet. 1980; 2:176-180
32. Sokol R.J. Alcohol and spontaneous abortion. Lancet. 1980; 2:1079.
33. Alpert J.J., Day N., Dooling E., et al. Maternal alcohol consumption and newborn assessment: methodology of the Boston City Hospital prospective study. Neurobehav Toxicol Teratol. 1981; 3:195-201.
34. National Institute on Alcohol Abuse and Alcoholism. Alcohol and your unborn baby. Rockville, Md.: Public Health Service, 1978. (DHEW publication no. (ADM)78–521).
35. Sokol R.J., Miller S.I., Reed G. Alcohol abuse during pregnancy: an epidemiologic study. Alcohol Clin Exp Res. 1980; 4:135-145
36. Little R.E. Moderate alcohol use during pregnancy and decreased infant birth weight. Am J Public Health. 1977: 67:1154-1156
37. Aase J.M. The fetal alcohol syndrome in American Indians: a high risk group. Neurobehav Toxicol Teratol. 1981; 3:153-156
38. Heinonen O.P., Slone D., Shapiro S. Birth defects and drugs in pregnancy. Littleton, Mass.: PSG, 1977.
39. Crombie D.L., Pinsent R.J.F.H., Slater B.C., Fleming D., Cross K.W. Teratogenic drugs — R.C.G.P. survey. Br Med J. 1970; 4:178-179
40. Kullander S., Källén B. A prospective study of drugs and pregnancy. 1. Psychopharmaca. Acta Obstet Gynaecol Scand. 1976; 55:25-33.
41. Kullander. A prospective study of drugs and pregnancy. 4. Miscellaneous drugs. Acta Obstet Gynaecol Scand. 1976; 55:287-295
42. Jick H., Holmes L.B., Hunter J.R., Madsen S., Stergachis A. First-trimester drug use and congenital disorders. JAMA. 1981; 246:343-346
43. Slone D., Siskind V., Heinonen O.P., Monson R.R., Kaufman D.W., Shapiro S. Aspirin and congenital malformations. Lancet. 1976; 1:1373-1375
44. Harron D.W.G., Griffiths K., Shanks R.G. Debendox and congenital malformations in Northern Ireland. Br Med J. 1980; 281:1379-1381
45. Cordero J.F., Oakley G.P., Greenberg F., James L.M. Is Bendectin a teralogen? JAMA. 1981; 245:2307-2310
46. MacMahon B. More on Bendectin. JAMA. 1981; 246:371-372
47. No evidence to justify ban on Debendox, says Department of Health. Pharm J. 1980; 224:109-110
48. Kolata G.B. How safe is Bendectin? Science. 1980; 210:518-519
49. Schardein J.L. Drugs as teratogens. Cleveland: CRC Press, 1976.
50. Wheatley D. Drugs and the embryo. Br Med J. 1964; 1:630.
51. Nelson M.M., Forfar J.O. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. Br Med J. 1971; 1:523-527
52. Shapiro S., Heinonen O.P., Siskind V., Kaufman D.W., Monson R.R., Slone D. Antenatal exposure to doxylamne succinate and dicyclomine hydrochloride (Bendectin) in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol. 1977; 128:480-485
53. Physicians#x0027; desk reference. 36th ed. Oradell, N.J.: Medical Economics Co. 1982: 1290.
54. Bunde C.A., Bowles D.M. A technique for controlled survey of case records. Curr Ther Res. 1963; 5:245-248
55. General Practitioner Research Group. General practitioner clinical trials: drugs in pregnancy survey. Practitioner. 1963; 191:775-780
56. le Vann L.J. Congenital abnormalities in children born in Alberta during 1961: a survey and a hypothesis. Can Med Assoc J. 1963; 89:120-126
57. Milkovich L., van den Berg B.J. An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol. 1976: 125:244-248
58. Greenberg G., Inman W.H.W., Weatherall J.A.C., Adelslein A.M., Haskey J.C. Maternal drug histories and congenital abnormalities, Br Med J. 1977; 2:853-856
59. Newman N.M., Correy J.F., Dudgeon G.I. A survey of congenital abnormalities and drugs in a private practice. Aust NZ J Obstet Gynaecol. 1977; 17:156-159
60. Smithells R.W., Sheppard S. Teratogenicity testing in humans: a method demonstrating safety of Bendectin. Teratology. 1978; 17:31-35
61. Michaelis J., Gluck E., Michaelis H., Koller S., Degenhardt K.-H. Teratogene Effekte von Lenotan? Dtsch Artztebl. 1980; 23:1527-1529
62. Clarke M., Clayton D.G. Safety of Debendox. Lancet. 1981; 1:659-660
63. Fleming D.M., Knox J.D.E., Crombie D.L. Debendox in early pregnancy and fetal malformation. Br Med J. 1981; 283:99-101.
64. Mitchell A.A., Rosenberg L., Shapiro S., Slone D. Birth defects related to Bendectin use in pregnancy. I. Oral clefts and cardiac defects. JAMA. 1981; 245:2311-2314
65. David T.J. Debendox does not cause the Poland anomaly. Arch Dis Child. 1982; 57:479-480
66. Morelock S., Hingson R., Kayne H., et al. Bendectin and fetal development: a study at Boston City Hospital. Am J Obstet Gynecol. 1982; 142:209-213
67. Sadusk J.F. Jr., Palmisano P.A. Teratogenic effect of meclizine, cyclizine, and chlorcyclizine. JAMA. 1965; 194:987-989
68. Briggs M.H., Briggs M. Sex hormone exposure during pregnancy and malformations. Adv Steroid Biochem Pharmacol. 1979; 7:51-89.
69. Janerich D.T., Piper J.M., Glebatis D.M. Oral contraceptives and birth defects. Am J Epidemiol. 1980; 112:73-79
70. Schardein J.L. Congenital abnormalities and hormones during pregnancy: a clinical review. Teratology. 1980; 22:251-270
71. WHO Scientific Group. The effect of female sex hormones on fetal development and infant health. WHO Tech Rep Ser. 1981; 657:1-76.
72. Smithells R.W. Oral contraceptives and birth defects. Dev Med Child Neurol. 1981; 23:369-372
73. Torfs C.P., Milkovich L., van den Berg B.J. The relationship between hormonal pregnancy tests and congenital anomalies: a prospective study. Am J Epidemiol. 1981; 113:563-574
74. Wilson J.G., Brent R.L. Are female sex hormones teratogenic? Am J Obstet Gynecol. 1981; 141:567-580
75. Cuckle H.S., Wald N.J. Evidence against oral contraceptives as a cause of neural-tube defects. Br J Obstet Gynaecol. 1982; 89:547-549
76. Shapiro S., Slone D. The effects of exogenous female hormones on the fetus. Epidemiol Rev. 1979; 1:110-123
77. Herbst A.L. Clear cell adenocarcinoma and the current status of DES-exposed females. Cancer. 1981; 48:484-488
78. Bibbo M., Gill W.B., Azizi F., et al. Follow-up study of male and female offspring of DES-exposed mothers. Obstet Gynecol. 1977; 49:1-8.
79. Antoniolo D.A., Burke L., Friedman E.A. Natural history of diethylstilbestrol-associated genital tract lesions: cervical ectopy and cervicovaginal hood. Am J Obstet Gynecol. 1980; 137:847-853
80. Sandberg E.C., Riffle N.L., Higdon J.V., Getman C.E. Pregnancy outcome in women exposed to diethylstilbestrol in utero. Am J Obstet Gynecol. 1981; 140:194-205.
81. Berger M.J., Goldstein D.P. Impaired reproductive performance in DES-exposed women. Obstet Gynecol. 1980; 55:25-27
82. Herbst A.L. Diethylslilbestrol and other sex hormones during pregnancy. Obstet Gynecol. 1981; 58: Suppl:35S-40S.
83. Reynolds E.H. Drug treatment of epilepsy. Lancet. 1978; 2:721-725
84. Montouris G.D., Fenichel G.M., McLain L.W. Jr. The pregnant epileptic: a review and recommendations. Arch Neurol. 1979; 36:601-603
85. Fedrick J. Epilepsy and pregnancy: a report from the Oxford Record Linkage Study. Br Med J. 1973; 2:442-448
86. Speidel B.D., Meadow S.R. Epilepsy, anticonvulsants and congenital malformations. Drugs. 1974; 8:354-365
87. Meadow R. Congenital malformations and seizure disorders in offspring of parents with epilepsy. Dev Med Child Neurol. 1979; 21:536-538
88. Nakane Y. Congenital malformation among infants of epileptic mothers treated during pregnancy — the report of a collaborative study group in Japan. Folia Psychiatr Neurol Jpn. 1979; 33:363-369
89. Smithells R.W. Environmental teratogens of man. Br Med Bull. 1976; 32:27-33.
90. Annegers J.F., Hauser W.A., Elveback L.R., Anderson V.E., Kurland L.T. Congenital malformations and seizure disorders in the offspring of parents with epilepsy. Int J Epidemiol. 1978; 7:241-247
91. Hanson J.W., Myrianthopoulos N.C., Harvey M.A.S., Smith D.W. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on fetal hydantoin syndrome. J Pediatr. 1976; 89:662-668
92. Shapiro S., Slone D., Hartz S.C., et al. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet. 1976; 1:272-275
93. Stumpf D.A., Frost M. Seizures, anticonvulsants, and pregnancy. Am J Dis Child. 1978; 132:746-748
94. Friis M.L., Broeng-Nielsen B., Sindrup E.H., Lund M., Fogh-Andersen P., Hauge M. Facial clefts among epileptic patients. Arch Neurol. 1981; 38:227-229
95. Fraser F.C., Metrakos J.D., Zlatkin M. Is the epileptic genotype teratogenic? Lancet. 1978; 1:884-885
96. Janz D. Haben Antiepileptika eine teratogene Wirkung bei Menschen? Dtsch Med Wochenschr. 1978; 103:485-487
97. Weber M., Schweitzer M., Mur J.-M., Andre M., Tridon P., Vert P. Epilepsie, médicaments antiépileptiques et grossesse. Arch Fr Pediatr, 1977; 34:374-383
98. Bjerkedal T., Czeizel A., Goujard J., et al. Valproic acid and spina bifida. Lancet. 1982; 2:1096-1097
99. Villasanta U. Thromboembolic disease in pregnancy. Am J Obstet Gynecol. 1965; 93:142-160
100. DiSaia P.J. Pregnancy and delivery of a patient with a Starr-Edwards mitral valve prosthesis: report of a case. Obstet Gynecol. 1966; 28:469-472
101. Goodman R.M., Gorlin R.J. Atlas of the face in genetic disorders. 2nd ed. St Louis: CV Mosby, 1977.
102. Shaul W.L., Hall J.G. Multiple congenital anomalies associated with oral anticoagulants. Am J Obstet Gynecol. 1977; 127:191-198
103. Hall J.G., Pauli R.M., Wilson K.M. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med. 1980; 68:122-140
104. Chaube S., Murphy M.L. The teratogenic effects of the recent drugs active in cancer chemotherapy. Adv Teratol. 1968; 3:181-237.
105. Jick H., Walker A.M., Rothman K.J., et al. Vaginal spermicides and congenital disorders. JAMA. 1981; 245:1329-1332
106. Huggins G., Vessey M., Flavel R., Yeates D., McPherson K. Vaginal spermicides and outcome of pregnancy: finding in a large cohort study. Contraception. 1982; 25:219-230
107. Rothman K.J. Spermicide use and Down#x0027;s syndrome. Am J Public Health. 1982; 72:399-401.
108. Shapiro S., Slone D., Heinonen O.P., et al. Birth defects and vaginal spermicides. JAMA. 1982; 247:2381-2384
109. Polednak A.P., Janerich D.T., Glebatis D.M. Birth weight and birth defects in relation to maternal spermicide use. Teratology. 1982; 26:27-38.
110. Mills J.L., Harley E.E., Reed G.F., Berendes H.W. Are spermicides teratogenic? JAMA. 1982; 248:2148-2151
111. Çavdar A.O., Arcasoy A., Baycu T., Himmetoglu O. Zinc deficiency and anencephaly in Turkey. Teratology. 1980; 22:141.
112. Laurence K.M., James N., Miller M.H., Tennant G.B., Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br Med J. 1981; 282:1509-1511
113. Smithells R.W., Sheppaid S., Schorah C.J., et al. Apparent prevention of neural tube defects by periconceptional vitamin supplementation. Arch Dis Child. 1981; 56:911-918
114. Warkany J. Terathanasia. Teratology. 1978; 17:187-192
115. Johnson E.M. Reversed susceptibility of lung to teratogenic insult. Adv Stud Birth Defects. 1979; 1:199-212.
116. Fabro S. Biochemical basis of thalidomide teratogenicity. In: Juchau MR, ed. The biochemical basis of chemical teratogenesis. New York: Elsevier/ North-Holland, 1981: 159-78.
117. Chung C.S., Rao D.C., Ching G.H.S. Population and family studies of cleft lip and palate. In: Melnick M, Bixler D, Shields ED, eds. Etiology of cleft lip and cleft palate. New York: Alan R Liss, 1980: 325-52.
118. Miller R.W. How environmental effects on child health are recognized. Pediatrics. 1974; 53:792-796
119. Carter C.O. Spina bifida and anencephaly: a problem in genetic-environmental interaction. J Biosoc Sci. 1969; 1:71-83.
120. Leck I. Causation of neural tube defects: clues from epidemiology. Br Med Bull. 1974; 30:158-163
121. MacMahon B., Yen S. Unrecognized epidemic of anencephaly and spina bifida. Lancet. 1971; 1:31-33
122. Owens J.R., Harris F., McAllister E., West L. 19-Year incidence of neural tube defects in area under constant surveillance. Lancet. 1981; 2:1032-1035
123. United States National Center for Health Statistics. Monthly Vital Statistics Report. Vol. 31. No. 5. Birth, marriages, divorces, and deaths for May 1982. Hyattsville, Md.: Public Health Service, August 1982: 1-10. (DHHS publication no. (PHS)82–1120).